Netupitant/palonosetron
| Combination of | |
|---|---|
| Netupitant | NK1 receptor antagonist |
| Palonosetron | 5-HT3 receptor antagonist |
| Clinical data | |
| Trade names | Akynzeo |
| AHFS/Drugs.com | akynzeo |
| MedlinePlus | a614053 |
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | A04AA55 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
Netupitant/palonosetron (trade name Akynzeo) is a fixed dose combination drug for prevention of acute and delayed chemotherapy-induced nausea and vomiting.[1] Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[2]
Contraindications
Netupitant/palonosetron is contraindicated during pregnancy.[3]
Adverse effects
The most common side effects are headache and constipation. The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[3]
Interactions
Further information: Netupitant § Interactions, and Palonosetron § Interactions
Pharmacology
Further information: Netupitant § Pharmacology, and Palonosetron § Pharmacology
References
- ↑ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014.
- ↑ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Retrieved 12 July 2016.
- 1 2 Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
This article is issued from Wikipedia - version of the 7/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.